financetom
Business
financetom
/
Business
/
Dynatrace's Fiscal Q1 Non-GAAP Earnings, Revenue Increase; Fiscal 2026 Outlook Raised
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Dynatrace's Fiscal Q1 Non-GAAP Earnings, Revenue Increase; Fiscal 2026 Outlook Raised
Aug 6, 2025 4:15 AM

06:57 AM EDT, 08/06/2025 (MT Newswires) -- Dynatrace ( DT ) reported fiscal Q1 non-GAAP earnings Wednesday of $0.42 per diluted share, up from $0.33 a year earlier.

Analysts polled by FactSet expected $0.38.

Revenue for the quarter ended June 30 was $477.3 million, compared with $399.2 million a year earlier.

Analysts polled by FactSet expected $467.5 million.

The company said it expects fiscal Q2 non-GAAP earnings of $0.40 to $0.41 per share on revenue of $484 million to $489 million. Analysts polled by FactSet expect non-GAAP earnings of $0.40 per share on revenue of $481.9 million.

Dynatrace ( DT ) said it now expects fiscal 2026 non-GAAP earnings of $1.58 to $1.61 per share, up from the previous range of $1.56 to $1.59. Analysts polled by FactSet expect $1.59.

Fiscal 2026 revenue is now estimated at $1.97 billion to $1.99 billion, from $1.95 billion to $1.97 billion previously. Analysts polled by FactSet expect $1.96 billion.

Shares of Dynatrace ( DT ) were up 4% in recent premarket activity Wednesday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ripple challenges industry giants with new stablecoin
Ripple challenges industry giants with new stablecoin
Oct 15, 2024
Oct 15 (Reuters) - Crypto firm Ripple launched a stablecoin pegged to the U.S. dollar on Tuesday, looking to disrupt a market in which the top two incumbents account for nearly 90% of the value. The venture marks a major milestone for Ripple, coming more than a year after a landmark win in a case against the Securities and Exchange...
BriaCell to Complete Patient Enrollment for Phase 3 Breast Cancer Study by Mid-2025; Shares Rise
BriaCell to Complete Patient Enrollment for Phase 3 Breast Cancer Study by Mid-2025; Shares Rise
Oct 15, 2024
11:49 AM EDT, 10/15/2024 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) said Tuesday that patient enrollment for its pivotal Phase 3 study of Bria-IMT in combination with an immune checkpoint inhibitor for metastatic breast cancer is on track for expected completion by mid-2025. The trial aims to enroll up to 354 patients, randomized 1:1 to receive either the BriaCell...
Looking At Duke Energy's Recent Unusual Options Activity
Looking At Duke Energy's Recent Unusual Options Activity
Oct 15, 2024
Investors with a lot of money to spend have taken a bullish stance on Duke Energy ( DUK ) . And retail traders should know. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this...
Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer
Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer
Oct 15, 2024
Jazz Pharmaceuticals plc ( JAZZ ) revealed topline results from the Phase 3 clinical trial evaluating Zepzelca (lurbinectedin) in combination with the PD-L1 inhibitor Roche Holdings AG’s (OTC:RHHBY) atezolizumab (Tecentriq) compared to atezolizumab alone when administered as a maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC) following induction therapy with carboplatin, etoposide and atezolizumab. The combination of Zepzelca and atezolizumab showed...
Copyright 2023-2026 - www.financetom.com All Rights Reserved